Pfizer (PFE) has acquired Metsera for up to $7.3 billion, including $4.9 billion upfront, aiming to enhance its cardiometabolic portfolio. The acquisition focuses on Metsera’s obesity drug candidates currently in clinical trials, supporting Pfizer’s long-term growth strategy in metabolic health.

Earlier, on September 30, 2025, Pfizer signed a key deal to support global healthcare stocks, reflecting broader trends of pharma firms negotiating drug prices with the U.S. administration.

Additionally, Pfizer plans to highlight advancements in respiratory health and infectious disease research at IDWeek 2025, showcasing ongoing innovation across multiple therapeutic areas.

The Metsera acquisition, combined with Pfizer’s strategic collaborations and research initiatives, positions the company to expand its pipeline and market leadership in cardiometabolic and specialty therapies.